<DOC>
	<DOCNO>NCT01243047</DOCNO>
	<brief_summary>This randomized phase II study comprise two treatment arm patient previously untreated metastatic recurrent colorectal cancer .</brief_summary>
	<brief_title>Intermittent Versus Continuous Tarceva Study</brief_title>
	<detailed_description>To evaluate two different schedule erlotinib combination modify XELOX regimen term response rate</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Age ≥ 18 year . ECOG performance status 02 . Histological proof adenocarcinoma colon rectum evidence metastatic disease . At least one unidimensionally measurable lesion diameter &gt; 20 mm use conventional CT MRI scan , &gt; 10 mm spiral CT No prior drug treatment chemotherapy metastatic disease . No prior HER2 EGFR inhibitor . No prior Oxaliplatin clinical setting . Absolute granulocyte count &gt; 1.5 x 109/L , platelet count &gt; 100 x 109/L , hemoglobin level &gt; 9.0 g/L , INR &lt; 1.5 . Adequate renal &amp; hepatic function : serum creatinine &lt; 1.5 x upper limit normal ( ULN ) calculate creatinine clearance &gt; 50ml/min , serum bilirubin &lt; 1.5 x ULN , ALT &lt; 2.5 x ULN &lt; 5 x ULN case liver metastasis , albumin level &gt; 30g/dL ) . Prior adjuvant neoadjuvant chemotherapy nonmetastatic CRC allow &gt; 3 month elapse since last dose chemotherapy . Prior open surgery allow &gt; 28 days* elapse since date surgery , wound heal satisfactory recovery complication surgery adequate . ( *For laparoscopic surgery , &gt; 14 day date surgery ) . No serious medical condition myocardial infarction within 6 month prior entry , medical condition might aggravate treatment Prior history malignancy , except basal cell cancer skin , cervical CIN . Treatment radiotherapy &lt; 30 day . Pregnant lactating female Sexually active male female ( childbearing potential ) unwilling practice contraception study . Patients recover surgery medical illness infection . Evidence central nervous system disease . Patients history uncontrolled seizure , central nervous disorder psychiatric disability judge investigator clinically significant precluding inform consent interfere compliance oral drug intake exclude study Patients lack physical integrity upper gastrointestinal tract malabsorption syndrome unable swallow tablet . Prior unanticipated severe reaction fluoropyrimidine therapy ( without document DPD deficiency ) . Interstitial pneumonia extensive symptomatic fibrosis lung . Requirement concurrent use antiviral agent sorivudine ( antiviral ) chemically related analogue , brivudine . Known peripheral neuropathy ≥ NCI CTC grade 1 . Current recent ( within 10 day prior study treatment start ) use fulldose oral anticoagulant ( e.g . warfarin ) thrombolytic agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Second line treatment metastatic colorectal cancer</keyword>
</DOC>